Hey, Kelly. So, yeah, Novo is now out with results earlier than expected. It was slated to report overnight just ahead of results from Eli Liy, but we now have Novo's full earnings release.So, Novo is raising its fullear guidance on both the top and bottom lines, not comparable to estimates due to being in constant currency, but the company is citing increased expectations for GLP1 product sales as the reason for the improved outlook. But Novo said it's expecting a sales decline within its US operations, wh ...

>> JUST INCHES AWAY FROM ALL-TIME HIGHS. 30 MINUTES UNTIL THE START OF YOUR CASH EQUITY TRADE. MICHAEL: BLOOMBERG OPEN INTEREST STARTS RIGHT NOW.DANI: COMING UP, ANOTHER RECORD IN SIGHT FOR THE S&P 500 AS A PACKED EARNINGS SLATE CATCHES RALLY. SPACEX STEPS INTO THE EARNINGS SPOTLIGHT WHILE OTHERWORLDLY DEMAND POWERS PALANTIR. IN OIL GIVES UP ITS GAINS AS HOPES RISE FOR A DIPLOMATIC BREAKTHROUGH BETWEEN THE.U.S.AND IRAN SOME OF THE STOCKS WE ARE WATCHING THIS MORNING, IT IS ABOUT EARNINGS AND THE AI TRADE. P ...

Best stocks in the market according to Josh Brown. Today spotlight >> shines on two biotechs. Tell us which ones.>> Yeah. Yeah. So uh we we p we published this uh yesterday and we wanted to do something that had nothing to do with data centers and GPUs and just take a break from that whole AI capex world that we've been living in for so long.Um, and we wanted to talk about stocks that are working away from that. And, uh, Insight is the first one we'll talk about. Not only is this name on the best stocks in ...

The Danish drugmaker said annual sales and operating profit should fall less than it previously expected following a boost in the second quarter. https://t.co/7wPq66Mr8N ...

The task ahead following America’s cuts to foreign aid is for researchers to make the best of the new reality. They have tools: in particular, a pipeline of promising drugs https://t.co/u3nYwg3NVN ...

Pfizer raised the midpoint of its 2026 sales forecast after reporting strong second-quarter demand for older medicines https://t.co/dQyR331CtS ...

Wall Street’s appetite for weight-loss drug stocks over the past four years has powered Eli Lilly to consistently trade above $1,000 per share. Now, some see the pharma giant’s stock as primed for a split. https://t.co/mULsEpYYXs ...

Merck boosted its 2026 sales outlook after strong demand for newer drugs helped to drive revenues higher in the second quarter. https://t.co/LqQpEXM0Fc ...

One of our big guiding principles is just simplicity. Um, so like when you look at a model like let's say chai 1, I think there are 23 distinct subm modules in chai 1. Um, and like when you're trying to iterate on something like that, it gets really hard because you're like I kind of I need to understand each of these subm modules independently. I need to understand all of their behaviors, their dynamics, and like that doesn't actually scale that well.Um, so like you can start to think, okay, how do I simpl ...

Market Trends & Macroeconomic Environment - S&P 500 closed above all key moving averages after a turbulent July with back-to-back gains[1], while the Nasdaq 100 and Nasdaq Composite each rose about 2%[119] - Oil prices dropped 5% on a weekly basis and 5% on a daily basis, having a significant downward impact on energy costs[2] - U.S.-led currency intervention to contain the drop in the yen kept Japan from selling U.S. Treasuries, contributing to a bond market rally and lower yields[3] - U.S. factory activity surged to the highest level since 2022, with manufacturers increasing headcount for the first time since 2023[5][6] - The Federal Reserve held the federal funds rate at 3.5% to 3.75%, while forward-looking inflation metrics remained anchored[17][20] - The default rate across 1,300 U.S. private debt borrowers rose to a high of 6%, though rating methodology differences across agencies contributed to varying default rate calculations[51][54] Corporate Earnings & Financial Performance - S&P 500 Q2 earnings growth reached 35% to 40%, largely driven by technology, while valuations dropped back down to some of the lowest levels seen since 2020[8][10] - Palantir reported strong Q2 results, raising its full-year revenue guidance from a range of $7.66 billion to a tight range of $8.15 billion to $8.16 billion[111] - On Semiconductor reported adjusted EPS of $0.74 and quarterly revenue of $1.6 billion, beating analyst estimates[115] - Amazon crossed a $3 trillion market cap for the first time, becoming the fifth company ever to reach this milestone, while Boeing shares rose 8% following FAA certification for the 737 Max 7[103][104][105] Industry Developments & Potential Risks - The White House outlined $200 billion in spending per year to support individual scientists and private research facilities, with up to $5 billion allocated toward AI research and streamlined FDA review processes[23][31][32] - Bristol-Myers Squibb and AstraZeneca held early-stage talks regarding a potential megamerger that could become the largest pharma deal in history, though AstraZeneca shares fell as much as 10% amid investor pushback[39][40] - Yum Brands faced pressure and a 3% share decline following a parasitic Cyclospora outbreak tied to iceberg lettuce in Michigan that prompted early health authority investigations[49][109] - Yellow Card raised a $40 million funding round backed by strategic investors including SC Ventures and Sony Innovation Fund to expand its global stablecoin infrastructure and cross-border payment accounts[159][160][162]